Vorapaxar, combination antiplatelet therapy, and stroke

Robert G Hart; Jonathan L Halperin; Jeffrey I Weitz

doi:10.1016/j.jacc.2014.09.038

Vorapaxar, combination antiplatelet therapy, and stroke

J Am Coll Cardiol. 2014 Dec 9;64(22):2327-9. doi: 10.1016/j.jacc.2014.09.038. Epub 2014 Dec 1.

Authors

Robert G Hart¹, Jonathan L Halperin², Jeffrey I Weitz³

Affiliations

¹ Population Health Research Institute, Hamilton Health Sciences, Department of Medicine (Neurology), McMaster University, Hamilton, Ontario, Canada. Electronic address: robert.hart@phri.ca.
² Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center, New York, New York.
³ Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 25465418
DOI: 10.1016/j.jacc.2014.09.038

No abstract available

Keywords: PAR-1 receptor; acute coronary syndrome; antiplatelet; intracerebral hemorrhage; peripheral arterial disease; platelet activation; platelet aggregation inhibitors.

Publication types

Editorial
Comment

MeSH terms

Brain Ischemia / drug therapy*
Brain Ischemia / epidemiology*
Coronary Thrombosis / diagnosis*
Coronary Thrombosis / prevention & control*
Drug-Eluting Stents*
Female
Humans
Lactones / administration & dosage*
Male
Pyridines / administration & dosage*
Receptors, Thrombin / antagonists & inhibitors*
Stroke / drug therapy*
Stroke / epidemiology*

Substances

Lactones
Pyridines
Receptors, Thrombin
vorapaxar